trending Market Intelligence /marketintelligence/en/news-insights/trending/8drdpzzprdq2zd4jjfkbxg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bioblast Pharma chairman/CEO Price steps down with 4 board members

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bioblast Pharma chairman/CEO Price steps down with 4 board members

Bioblast Pharma Ltd. said chairman and CEO Fredric Price is stepping down and leaving the board, along with four independent board members, effective July 31.

Price said in the company's July 26 press release that "the board has determined that it is in the best interests of the company's shareholders to further reduce expenses and to turn over the business development process to a new board and a new CEO."

Warren Wasiewski will also step down as chief medical officer with the biotechnology company, which has offices in Tel Aviv and New York.

Dalia Megiddo, one of Bioblast's co-founders, will continue to serve on the board and also fill both the CEO and chief medical officer roles.

Gili Cohen, Eyal Gibor, Tomer Yossef and Ran Weinstock all were approved by the board to be new members. Cohen rejoins Bioblast, having previously been an external director for the company from July 2014 to January 2017.

The company is seeking a partner to develop an experimental, intravenous form of the medicine trehalose for certain neuromuscular diseases.